

Saving Lives By Developing Next Generation Of Natural & Safe Antibacterial Solutions

# WE KILL PATHOGENS.






















# THE NEED: UKRAINIAN SOLDIER WITH PAN-RESISTANT PATHOGEN UNTREATABLE?

















# NEXT GENERATION OF NATURAL & EFFECTIVE ANTIBACTERIAL SOLUTIONS: BACTERIOPHAGES



# **BACTERIOPHAGES**

### NATURAL MICROORGANISMS THAT KILL BACTERIA & TREAT INFECTIONS




Fully Biodegradable



No side-effects



Adaptability to Resistance





Target specific



Stable & scalable





Self-replication



# **PHAGE FACTS**

### **PHAGE REPLICATION CYCLES**







# **MEDEA PROCESS**

### PHAGE ISOLATION, EVOLUTION, CHARACTERIZATION AND FORMULATION



Discovering natural phages and creating selective and adaptive biobanks




Designing most effective Cocktails with selected synergetic phages




3


Phage adaptation for different application areas and modalities


2











• 10-100x cost efficiency\*





### **COMPETITIVE ADVANTAGE:**

We use our inhouse automation platform technology to create large & up-to-date biobanks and develop optimal products!


MEDEΛ Bioreactor\*\*





## **MAGISTRAL PHAGE THERAPY**


#### PERSONALISED DRUG SUBSTANCE R&D & MANUFACTURING




#### Gutachten Trojok et al. 2022











#### **CURRENT PRODUCT DEVELOPMENT**

### DEVELOPING ANTIBACTERIAL THERAPEUTIC DRUG FOR DOGS



Why Otitis Externa?

**High Resistance to Antibiotics** 

**Recurrent & Chronic Cases** 

**Topical Delivery Ideal for Phages** 

Low Price-Sensitivity of dog owners

**Positive Efficacy Results in previous clinical trials** 

### **Compared to alternatives**

- ✓ Natural & targeted
- ✓ Effective against MDR Bacteria
- No side-effects



## **OUR CURRENT PIPELINE**

#### **VETERINARY THERAPEUTIC DRUGS**

Disease	Discovery	Pre-Clinical	Clinical
Canine Otitis Externa			
Undisclosed			

# FUTURE POSSIBILITIES







**Feed Supplements** 



# **OUR ACHIEVEMENTS & NEXT STEPS**

2 Million EUR Pre-Seed Funding & Grants in 2023



Team of 10 employees



#### **Achievements & Prizes**





WE ARE LOOKING FOR
5 Million EUR Seed Investment



### **FOUNDING TEAM**



Managing Director Dipl. Biologist



- 11 years in biotech R&D
- Advisor of German Parliament



Giorgi Khubua

**Managing Director** M.Sc. Management



- Forbes 30 under 30
- Entrepreneur with Exit



**Dr. Elene Kakabadze** 

Chief Scientific Officer PhD, Microbiology



- >12 years in phage R&D
- Several scientific papers



+11 world's renowned experts in advisory board





Rheinland-Pfalz ist Zukunftsstandort der Biotechnologie!

Plch war zu Besuch bei der Medea Biopharma GmbH. Ein beeindruckendes Beispiel für unser Innovationspotenzial. Mit ihrer Forschung an umweltfreundlichen antibakteriellen Lösungen auf Basis von Bakteriophagen trägt sie aktiv zur Bekämpfung antimikrobieller Resistenzen bei – einer der größten globalen Herausforderungen unserer Zeit.

"Wir werden mit großer Offenheit schauen, wie wir bei Themen der Regulatorik und Arzneimittelzulassung ganz konkret unterstützen können."

Ministerpräsident Alexander Schweitzer.





